Your Paraquat Parkinson’s Case Is Not Gone — The Supreme Court Narrowed the Door, But It Did Not Close It
You have Parkinson’s disease. You spent years — maybe decades — working in agriculture, mixing chemicals, loading tanks, walking behind sprayers as the mist drifted over you in the Texas heat. You may have used paraquat. You may have been near it. And now your hands shake when you try to hold a coffee cup. Your legs freeze in doorways. Your body moves slower every year, and the medications are escalating, and the doctor says this is progressive and incurable, and then you saw the news: the United States Supreme Court just ruled for the company that makes Roundup, and the headline said the ruling “clouds the case against paraquat.”
You are wondering whether the courthouse door just slammed shut.
It did not. The door is narrower than it was a week ago. But it is not closed. And something buried in the Supreme Court’s reasoning — something most of the headlines missed — may actually make the paraquat case stronger than the Roundup case in one critical way.
We are Attorney911 — The Manginello Law Firm. We handle toxic tort cases for workers and families across the country, and we have spent our careers fighting for people who were poisoned on the job and never told the danger was there. What follows is our straight analysis of what the Supreme Court just did, what it means for your paraquat case, and what we do about it. This is legal information, not legal advice — every case turns on its own facts — but it is written by the senior trial attorneys who would handle a case like yours, and it is written for the person sitting at a kitchen table at 2 a.m. wondering if they still have a claim.
They do. Here is why.
What the Supreme Court Actually Held in Monsanto Co. v. Durnell
The Supreme Court’s 7-2 decision in Monsanto Co. v. Durnell resolved one specific legal question: whether the Federal Insecticide, Fungicide, and Rodenticide Act — known as FIFRA — blocks state-law failure-to-warn claims when the EPA has approved a pesticide’s label without the warning a plaintiff says should have been there.
The Court said yes. Justice Kavanaugh, writing for the majority, accepted the argument that once the EPA approves a pesticide for sale without a particular warning on its label, a state jury cannot hold the manufacturer liable for failing to add one the agency never required. The reasoning turned on FIFRA’s preemption clause, which bars states from imposing labeling requirements that differ from what federal law demands:
“A State may not impose or continue in effect any requirements for labeling or packaging in addition to or different from those required under this Act.”
That is FIFRA’s preemption clause. The Court read it to mean: if the federal government’s approved label does not carry a cancer warning, a state jury verdict requiring one is a state requirement “in addition to or different from” what federal law allows — and it is therefore preempted. The result: John Durnell’s $1.25 million jury verdict, won in Missouri state court after he developed non-Hodgkin lymphoma from years of Roundup use, was overturned. That verdict is no longer standing. It was reversed by the Supreme Court.
Justice Jackson, in dissent, wrote that the majority misunderstood FIFRA’s requirements, misread the scope of its preemption clause, and left Durnell without any remedy for serious harm. The dissent matters because it lays out the counter-argument that future courts will be asked to reconsider — but as of today, the majority’s holding is the law.
Why “the Label Is the Law” — and Who Controls What It Says
To understand why this ruling matters so much, you need to understand what a pesticide label actually is. It is not marketing copy glued to the jug. It is a legal document — the detailed instructions, use restrictions, and health-and-safety warnings that the EPA reviews and must approve before the product can be sold legally in this country. The manufacturer generally cannot add, drop, or alter a warning without the agency’s sign-off. Selling a pesticide with a label that departs from the approved version can expose the company to civil and even criminal penalties.
In practice, the label is the law. And that means the question of who controls its wording determines who can be held to account for what it leaves out.
Here is the problem the Supreme Court just created. The label-approval process is a long back-and-forth between the manufacturer and the EPA, with the company providing much of the underlying data and studies and the agency doing the review. If the company gives the EPA incomplete science — if it runs studies that show a risk and buries them, or if it frames the data in a way that minimizes the danger — the EPA may approve a label that does not warn about a hazard the company privately knew about. Before Durnell, a state jury could hear evidence that the company hid the risk and hold it accountable for the missing warning. After Durnell, that avenue is largely foreclosed. The company can say: the EPA approved the label, the label did not carry the warning, and federal law bars you from requiring one.
That is the devastating part of the ruling — not just for Roundup plaintiffs, but for anyone who was injured by a pesticide whose label the EPA approved without the warning that should have been there.
The Paraquat Distinction: Why Your Case Is Different From the Roundup Case
Here is the thing that matters most, and it is the thing most of the coverage compressed into a single sentence or missed entirely.
The Supreme Court’s preemption logic in Durnell turned on one specific factual predicate: the EPA had explicitly studied whether glyphosate — the active ingredient in Roundup — causes cancer, and it affirmatively concluded that glyphosate was “not likely” to be carcinogenic. The Court’s reasoning depended on the existence of a definitive federal safety finding. The agency looked at the cancer question, the agency answered it, and the answer was “no cancer risk.” Because the federal government had made that affirmative determination, the Court reasoned, a state jury could not override it by imposing a warning the agency had decided was unnecessary.
For paraquat, the EPA never made that kind of finding. Not even close.
The EPA looked at whether paraquat causes Parkinson’s disease and concluded only that the evidence was “insufficient” to establish a link. That is not a finding of safety. It is not an affirmative clearance. It is the agency saying: we are not sure. And then, in 2025, facing a legal challenge to that interim determination, the EPA withdrew it entirely, reopened the review, and has not issued a revised finding since.
That means there is no standing federal determination on the paraquat-Parkinson’s question — in either direction. The EPA has not said paraquat causes Parkinson’s. But it also has not said paraquat does not cause Parkinson’s. The agency never decided. The question was left open.
This is the crack in the preemption wall. The Durnell majority’s reasoning depends on the EPA having made an affirmative safety finding that a state-law claim would contradict. Where no such finding exists — where the agency explicitly declined to decide the relevant safety question and then withdrew even its tentative conclusion — the argument that federal label approval preempts a state-law claim is materially weaker. How can a state-law claim be “in addition to or different from” a federal requirement when the federal government never established a requirement on the point at all?
This argument must be briefed aggressively at the motion-to-dismiss stage in the paraquat MDL. It is the single strongest distinction between the Roundup litigation, which Durnell gutted, and the paraquat litigation, which has a path to survive. Both sides in the paraquat litigation told the Supreme Court that the Durnell ruling could determine whether paraquat claims live or die. The answer depends on whether the courts accept this distinction — and it is a real, principled distinction that the Durnell majority’s own reasoning left open.
The Theories That Survive: What We File Instead of Failure-to-Warn
Even setting aside the paraquat-specific preemption argument, three legal theories survive the Durnell ruling because they do not depend on label warnings at all. These are the theories that every paraquat plaintiff’s case must now be built on.
Design Defect — The Product Itself Is Unreasonably Dangerous
A design defect claim says the product is inherently unreasonably dangerous in its chemical design or formulation, independent of any labeling deficiency. This theory does not ask the jury to require a different label — it asks the jury to find that the product, as designed, should not have been sold in its current form because a safer alternative design existed and was feasible.
For paraquat, the design defect theory would argue that the chemical formulation itself — a bipyridyl herbicide whose structure generates reactive oxygen species and causes oxidative stress in dopaminergic neurons — is inherently unreasonably dangerous for its intended use, and that safer alternative weed-control methods or formulations were available and feasible. Proving this requires a chemical engineering or formulation expert who can testify about alternative designs, their feasibility, and why the manufacturer chose not to pursue them.
The defense will argue that design defect is just failure-to-warn in disguise — that the plaintiff is really saying “you should have warned about the design danger.” The counter is to plead and prove the design theory with clean separation from any label-based duty. The question is not what the label should have said. The question is whether the product should have been designed this way at all.
Manufacturing Defect — Something Went Wrong in the Batch
A manufacturing defect claim says that a specific lot or batch of the product deviated from the manufacturer’s intended formulation or specifications, and that deviation caused the injury. This is independent of label requirements and is not reached by the FIFRA preemption analysis the Court articulated in Durnell.
This theory requires evidence that the specific paraquat product the plaintiff was exposed to was somehow different from what the manufacturer intended — a contamination, a concentration error, a formulation drift. It is a narrower theory than design defect and requires product-specific proof that ties the plaintiff’s exposure to a specific defective batch. But where the evidence supports it, it is completely outside the preemption zone.
Fraudulent Concealment — What They Knew and Hid
This is the theory that may carry the most weight — and the one that opens the door to punitive damages.
Fraudulent concealment says the manufacturer intentionally withheld or suppressed evidence of health risks from the EPA, the scientific community, and the public. It does not depend on label warnings. It depends on what the company knew, when it knew it, and what it chose to do with that knowledge — specifically, whether it concealed, minimized, or misrepresented data showing a link between paraquat and Parkinson’s disease.
The discovery target here is laser-focused: internal corporate studies on the paraquat-Parkinson’s link, communications between Syngenta’s scientists and its regulatory affairs personnel, documents underlying the company’s EPA submissions, evidence of data suppression or selective reporting, and the internal deliberations behind Syngenta’s April announcement that it would stop producing paraquat.
If discovery reveals that the company’s own scientists studied the Parkinson’s risk, found evidence of a link, and that those findings were suppressed or misrepresented in communications to the EPA — that is fraudulent concealment. And fraudulent concealment can support punitive damages, which are the engine that turns a modest compensatory case into one with real settlement leverage.
The defense will argue that fraudulent concealment is preempted too, or that the company’s EPA submissions were complete and accurate. The counter is in the documents — and the documents are what the discovery process is designed to force into the light.
The Corporate Defendants: Who Made Paraquat, Who Distributed It, and Who Is Hiding Behind Whom
A toxic tort case is only as strong as the defendant you can reach. In the paraquat litigation, the defendants are not a single company — they are a web of corporate entities, each with a different role and a different argument for why someone else should bear the blame.
Syngenta — The Manufacturer
Syngenta is the primary manufacturer of paraquat, sold under the brand name Gramoxone. Syngenta is owned by a Chinese state-owned conglomerate — ChemChina, which was later merged into Sinochem Holdings. The ownership structure is itself a story: China has barred paraquat from its own farms, yet through its state-owned conglomerate, it owns the company that still sells paraquat in the United States. More than 70 countries have banned paraquat outright. In late May, Vermont became the first U.S. state to ban it. The fact that the manufacturer’s own home country will not let the chemical touch its soil is a fact a jury should hear.
In April, Syngenta announced it would stop producing paraquat, claiming the decision was made “solely for commercial reasons.” That public statement is a discovery target of the highest order. The internal deliberative documents behind that decision — emails, board memos, risk assessments, communications between scientists and executives — should reveal whether health concerns, mounting liability, or regulatory risk drove the decision while the company told the public it was purely a business choice. If the internal documents say one thing and the public statement says another, that gap is evidence of concealment. And those documents are recent — they were created in the months leading up to the April announcement. They must be preserved immediately.
Chevron — The Historical Distributor
Chevron is a co-defendant in the paraquat litigation because of its historical role in distributing and formulating paraquat products in the United States. The original developer of paraquat was Imperial Chemical Industries (ICI), a British chemical company. Chevron entered into an agreement to distribute paraquat in the U.S. market, and its chemical division handled the product for years before Syngenta acquired ICI’s paraquat business. Chevron’s involvement is historical, but historical liability in product liability law can be deep — a company that distributed a defective product can be held accountable even if it later exited the market, depending on the jurisdiction’s successor liability and distributor liability rules.
Monsanto / Bayer AG — The Roundup Manufacturer
Bayer AG, the German pharmaceutical and chemical giant, inherited the Roundup litigation when it acquired Monsanto in 2018. Bayer has already paid approximately $11 billion to settle roughly 100,000 Roundup claims. In February, Monsanto proposed a separate $7.25 billion class settlement to cover most of the remaining current and future claimants, with a hearing on the deal scheduled for July. The Durnell ruling reshapes that calculus — by foreclosing the failure-to-warn theory that anchored the largest jury verdicts, it strips remaining plaintiffs of their most potent claim and strengthens Bayer’s hand in pressuring holdouts to accept the settlement rather than go it alone.
For Roundup plaintiffs, the post-Durnell landscape is genuinely harder. Design defect and fraudulent concealment theories remain, but the failure-to-warn theory was the engine that drove the largest verdicts, and that engine is now largely gone. The $7.25 billion class settlement may be the best available resolution for many glyphosate claimants — but each person’s case must be evaluated individually against the terms of the class deal, and no one should accept a class settlement without understanding whether their individual case is worth more on its own.
The Medicine: Parkinson’s Disease from Paraquat Exposure
Parkinson’s disease is the world’s fastest-growing neurological disorder. It is progressive. It is incurable. And for the person living with it, it is a slow theft of everything the body used to do without thinking.
The Mechanism — How Paraquat Attacks the Brain
Parkinson’s disease is caused by the death of dopamine-producing neurons in the substantia nigra, a region deep in the brain that controls voluntary movement. Dopamine is the chemical messenger that tells your muscles to move smoothly and on command. As those neurons die, dopamine levels fall, and the symptoms emerge.
Paraquat’s chemical structure is similar to MPTP — 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine — a compound that definitively causes Parkinson’s in humans. That link was discovered in the 1980s when a group of drug users developed instant, irreversible Parkinsonism after exposure to a synthetic heroin contaminant that turned out to be MPTP. It was one of the most dramatic discoveries in neurology: a single chemical compound could selectively destroy the exact neurons that Parkinson’s destroys. Paraquat’s structural similarity to MPTP is not a coincidence — it is the biological foundation of the concern.
Paraquat generates reactive oxygen species — unstable molecules that damage cells through oxidative stress. In the brain, dopaminergic neurons in the substantia nigra are particularly vulnerable to oxidative stress because of their high metabolic demand and their dopamine metabolism, which itself produces reactive byproducts. Paraquat exposure, the science suggests, accelerates the oxidative damage that kills those neurons. The mechanism is studied, documented, and biologically plausible.
The Symptoms — What the Family Watches Happen
The cardinal symptoms of Parkinson’s are tremor (the shaking that starts in one hand and spreads), rigidity (the stiffness that makes every movement feel like pushing through wet concrete), bradykinesia (the terrifying slowness of movement that turns buttoning a shirt into a five-minute ordeal and walking across a room into a project), and postural instability (the loss of balance that makes falls a constant, life-threatening risk).
The family sees it before the neurologist confirms it. The handwriting gets smaller. The voice gets softer. The facial expression freezes into a mask. The arms stop swinging when the person walks. The person stops smelling things — loss of olfaction is often one of the earliest signs, preceding motor symptoms by years. And then the tremor comes, and the diagnosis follows, and the family learns that this is not going to get better.
The Progression — 20 to 30 Years of Decline
Parkinson’s is not a death sentence on day one. It is a 20-to-30-year sentence of progressive decline. In the early years, medications can mask the symptoms effectively. Levodopa (usually combined with carbidopa as Sinemet or Rytary) replaces the missing dopamine, and for a time, the person functions almost normally. But the disease progresses, the medication’s effectiveness wanes, and the side effects mount — dyskinesias (involuntary writhing movements caused by the medication itself), “off periods” where the medicine wears off unpredictably and the person freezes, and eventually dementia in many patients.
As the disease advances, the treatment escalates. Dopamine agonists are added. MAO-B inhibitors are added. Deep brain stimulation — a surgical procedure in which electrodes are implanted in the brain and connected to a pacemaker-like device in the chest — may be offered for advanced motor symptoms. The surgery is brain surgery. It carries real risks. And it is not a cure — it manages symptoms.
Eventually, many Parkinson’s patients require skilled nursing facility placement. The falls become too dangerous. The cognitive decline makes independent living impossible. The family cannot provide the level of care the disease demands. And the cost — the medication, the therapy, the surgeries, the home modifications, the assistive devices, the wheelchair, the hospital bed, the caregiver, the facility — accumulates across decades into a number that a life-care planner must build, line by line, year by year.
The Latency — Why the Clock Starts Late
Parkinson’s disease, like other toxin-induced neurological conditions, has a latency period — the time between exposure and the onset of symptoms. For pesticide-induced Parkinson’s, the latency can be years to decades. A farmworker who sprayed paraquat in their thirties may not develop tremor until their fifties or sixties. This latency matters in two ways: medically, it makes the connection between exposure and disease harder to see (the worker has long since moved on from that job and may not even remember the chemical’s name); and legally, it means the statute of limitations may not have started running when the exposure occurred — it may have started when the diagnosis was made or when the connection between the disease and the exposure was or should have been discovered.
The Evidence Clock: What Is Disappearing and How Fast
The evidence that will make or break a paraquat case is not sitting in a filing cabinet waiting to be picked up. It is sitting on corporate servers with retention policies designed to overwrite it, in the email accounts of scientists who have retired or moved on, and in the deliberative files behind a production-cessation decision that a company would rather you not examine too closely. Every day that passes without a preservation letter on file is a day the defense is counting on.
Corporate Internal Studies and Research on the Paraquat-Parkinson’s Link
These are the documents that prove manufacturer knowledge — the foundation for fraudulent concealment and the engine for punitive damages. Internal studies, toxicology reports, risk assessments, and research findings that the company’s own scientists generated are the single most valuable category of evidence in this case. They are subject to corporate document retention policies. Preservation letters and litigation holds must be issued immediately. The MDL may already have some of these under hold, but individual claimants should ensure their claims are tagged to existing holds and that any documents specific to their exposure period are specifically requested.
EPA Submission Correspondence and Label Revision History
These show what the manufacturer told the EPA — and just as importantly, what it did not tell the agency. The gap between what the company’s internal studies showed and what it represented to the EPA is the fraudulent concealment case. Federal records are archived, but the corporate-side correspondence that supports or contradicts the EPA submissions may be subject to retention schedules or privilege assertions. These need to be demanded in discovery with specific, targeted requests.
Internal Emails and Communications Between Scientists, Regulatory Affairs, and Executives
These prove knowledge, the timing of knowledge, and any decision to suppress or misrepresent health data. Standard corporate email retention cycles can overwrite within three to seven years. This is urgent for any claimant not already covered by the MDL’s litigation hold. An email from a Syngenta toxicologist to the regulatory affairs department saying “we need to look at this Parkinson’s data before we submit to EPA” is the kind of document that wins a fraudulent concealment claim — and it is the kind of document that corporate retention policies are designed to erase.
Manufacturing and Design Specifications and Alternative-Formulation Studies
These support the design defect theory — they show whether a safer alternative design was considered and rejected. They may be subject to document retention schedules. And the product-line cessation announcement increases the risk that design and manufacturing archives will be boxed up, moved, or disposed of as the company winds down production. A preservation letter targeting these specific records must go out now, not after the production line is shuttered.
Employee Testimony from Scientists, Toxicologists, and Regulatory Affairs Personnel
Corporate knowledge lives in people, not just documents. The scientists who ran the internal studies, the regulatory affairs personnel who prepared the EPA submissions, the executives who decided what to disclose and what to withhold — their depositions are where the documents come alive. But personnel turnover is a real risk. Key employees retire, relocate, become unavailable, or their memories fade. Depositions in the MDL may capture some of this testimony, but individual claimants and their counsel should track witness availability and move to preserve testimony while it is still fresh.
Syngenta’s Production Cessation Documentation and Internal Rationale
The company publicly claimed its decision to stop paraquat production was “solely for commercial reasons.” Discovery should test whether that public statement was true. The internal deliberative documents — emails, meeting minutes, board presentations, risk assessments, liability projections — created during the cessation decision are recent and should still exist. They must be preserved immediately. If those documents show that health concerns, liability exposure, or regulatory risk drove the decision while the company told the public it was purely commercial, that gap is evidence of misleading public statements and consciousness of risk. And the timeline — the cessation announcement came just weeks before the Supreme Court ruling — raises its own questions about what the company knew and when.
What the Defense Will Do: The Playbook and Our Counter to Each Move
The defense bar is not going to let Durnell sit on the shelf. They will deploy it aggressively. Here are the plays you should expect and what we do about each one.
Play 1: The Durnell Motion-to-Dismiss Sweep
What they do: The defense files a motion to dismiss on every claim that functionally operates as a failure-to-warn claim, regardless of how it is pleaded. If the complaint says “the company failed to warn of the Parkinson’s risk” in any form — even buried inside a design defect count — the defense will argue it is preempted under Durnell.
Our counter: We plead non-label theories with clean separation from any warning-based duty. The complaint must not say “you should have warned” anywhere near a design defect or fraudulent concealment count. The design defect theory asks whether the product should have been designed this way at all — not whether the label should have said something different. The fraudulent concealment theory asks what the company hid from the EPA — not what the label should have told the user. These are fundamentally different questions from failure-to-warn, and the pleading must make that crystal clear.
Play 2: The “EPA Already Decided” Argument
What they do: The defense argues that the EPA’s “insufficient” finding on the paraquat-Parkinson’s link is equivalent to the affirmative cancer clearance that drove the Durnell ruling — that the agency looked at the question and resolved it, even if the resolution was “we can’t prove it.”
Our counter: “Insufficient evidence” is not a finding of safety. It is a finding of uncertainty — the agency saying it does not have enough data to decide. And the EPA withdrew even that interim determination in 2025, reopened the review, and has not issued a revised finding. There is no standing federal determination on the paraquat-Parkinson’s question. The Durnell preemption logic depends on the existence of an affirmative federal safety finding that a state-law claim would contradict. Where no such finding exists, preemption does not apply with the same force. This distinction must be briefed aggressively at the motion-to-dismiss stage.
Play 3: The Class Settlement Squeeze
What they do: Bayer’s proposed $7.25 billion class settlement is designed to resolve the remaining Roundup claims. The settlement terms, combined with the Durnell ruling, will be used to pressure holdouts: take the class deal now, because if you go it alone, your failure-to-warn claim is dead and your remaining theories are harder to prove.
Our counter: Each person’s case must be evaluated individually against the class settlement terms. A paraquat plaintiff with strong exposure proof, a solid Parkinson’s diagnosis, and a case built on fraudulent concealment and design defect may be worth substantially more than what the class settlement offers. The class settlement is a business decision by the defendant to cap its exposure — it is not a measure of what any individual case is worth. No one should accept a class settlement without understanding whether their individual case is worth more on its own.
Play 4: The Daubert Challenge on General Causation
What they do: The defense files a motion to exclude the plaintiff’s general causation experts under the Daubert standard, arguing that the scientific evidence linking paraquat to Parkinson’s is unreliable and should not be admitted. This is the play that threatened the paraquat MDL before Durnell, and it remains the single greatest case-killing risk.
Our counter: We retain the strongest possible experts — neurologists who specialize in movement disorders, toxicologists with pesticide-specific expertise, epidemiologists who have published on the paraquat-Parkinson’s link, occupational medicine specialists who can reconstruct exposure, and chemical engineers who can address design defect alternative feasibility. General causation in toxic tort cases is fought on dose-response evidence, mechanism plausibility, and epidemiological consistency. The MPTP structural similarity, the oxidative stress mechanism, the epidemiological studies showing elevated Parkinson’s rates in agricultural workers with paraquat exposure — these are the building blocks of a causation case that must be assembled with precision and presented by experts whose credentials the defense cannot dismiss.
Play 5: Alternative Causation — “You Can’t Prove Paraquat Caused Your Parkinson’s“
What they do: The defense argues that Parkinson’s disease is common in the general population, has many causes (genetics, age, head trauma, other pesticides), and that the plaintiff cannot prove that this Parkinson’s was caused by this paraquat exposure rather than something else.
Our counter: We build the exposure history with specificity — where the person worked, what they sprayed, how often, for how long, what the application method was, what the wind conditions were, whether they wore protective equipment (and whether the label’s PPE requirements were adequate). We retain an occupational medicine expert who can reconstruct the dose. We use the epidemiological literature showing elevated Parkinson’s risk in paraquat-exposed populations. And we argue that the mechanism — oxidative stress killing dopaminergic neurons — is consistent with the disease the plaintiff developed. Causation in toxic tort is not about certainty. It is about whether the exposure was a substantial contributing factor to the disease. That standard, properly supported, is met.
How a Case Is Actually Built: From the Day You Call to the Day a Number Is on the Table
Here is how a paraquat Parkinson’s case is actually built, step by step, by lawyers who know the path.
Week one: The preservation letter goes out. It targets every category of perishable evidence — corporate internal studies, EPA submission correspondence, internal emails between scientists and regulatory affairs, manufacturing and design specifications, the production cessation deliberative file, and employee testimony. The letter goes to Syngenta, to Chevron, to any other defendant, and to every third-party custodian who may hold relevant records. The day you call is the day the clock starts working for you instead of against you.
Weeks two through four: We build the exposure history. Where did you work? What did you spray? When? How often? For how many years? What was the application method — backpack sprayer, tractor-mounted spray rig, aerial application? Did you mix the chemical yourself? Did you wear protective equipment? Was the equipment adequate? We gather employment records, applicator licensing records, agricultural use records, purchase records, and any documentation that places you in proximity to paraquat during a specific period.
Weeks four through eight: We build the medical proof. You need a neurological evaluation by a movement-disorder specialist — not just a general neurologist, but someone who diagnoses Parkinson’s for a living. The diagnosis must be formal and documented. We exclude alternative causes where possible. We establish the timing of symptom onset relative to exposure. We gather every medical record — the first visit where the tremor was noted, the first MRI, the first neurological exam, the medication history, the progression documentation.
Months two through six: Expert witnesses are retained. A movement-disorder neurologist addresses specific causation — whether your Parkinson’s is consistent with paraquat exposure. A toxicologist addresses the mechanism and the dose. An epidemiologist addresses the population-level evidence. An occupational medicine specialist reconstructs your exposure. A chemical engineer addresses design defect and alternative formulation feasibility. Each expert’s work builds on the others — the toxicologist’s mechanism supports the neurologist’s causation opinion, the epidemiologist’s population data supports the toxicologist’s dose assessment.
Months six through eighteen: Discovery. This is where the documents come out. Interrogatories, document requests, depositions. The corporate knowledge is the target — what did Syngenta’s scientists know about the Parkinson’s link, when did they know it, what did they tell the EPA, what did they withhold, what did the board discuss when it decided to stop production? The depositions of scientists, regulatory affairs personnel, and executives are where the documents are explained, challenged, and pinned down under oath.
The bellwether process: The paraquat cases are consolidated in a multidistrict litigation before a federal judge in the Southern District of Illinois. The MDL process includes bellwether cases — selected test cases that go to trial first, to see how juries respond to the evidence and to establish settlement value. The bellwether results shape the settlement framework for the remaining cases. Your case may be part of the MDL or it may be filed individually, depending on the strategy. But the bellwether results will influence what the defendant is willing to offer.
The number: At the end, a number is built from all of it — the life-care plan (every medication, every therapy session, every surgery, every home modification, every assistive device, every caregiver hour, every year of skilled nursing facility care, projected across 20 to 30 years and reduced to present value), the lost earning capacity (the wages you will never earn because Parkinson’s took away your ability to work), the non-economic damages (the pain, the loss of independence, the loss of the life you planned, the fear of what is coming), and potentially the punitive damages (if discovery proves the company knew and concealed). That number is what the defendant is asked to pay. And the strength of the proof behind it is what determines whether they do.
What Your Case May Be Worth
Case value in the paraquat litigation depends on several variables: the strength of your exposure proof, the quality of your medical documentation, the venue where your case would be heard, whether the case is part of the MDL bellwether process or on an individual track, and — most critically — the quality of the corporate-knowledge evidence obtained in discovery.
Individual claimant values in comparable toxic tort cases range broadly. Pre-Durnell, paraquat Parkinson’s claims carried estimated values from approximately $250,000 on the low end to $5,000,000 or more on the high end, depending on the factors above. Post-Durnell, the loss of the failure-to-warn theory materially reduces per-claimant value and settlement leverage for claims that relied primarily on that theory. But paraquat claims retain higher residual value than Roundup claims for three reasons: the EPA never made a definitive Parkinson’s finding (potentially limiting preemption), fraudulent concealment and design defect theories remain viable and are not label-dependent, and Syngenta’s production cessation announcement suggests potential consciousness of risk that supports both liability and punitive damages theories.
For context, Bayer’s aggregate Roundup settlement exposure was approximately $11 billion across nearly 100,000 claims, with a proposed additional $7.25 billion class settlement. These are aggregate figures across an entire mass tort — they do not represent individual claimant values. Individual claimant value depends entirely on the specific facts of each case.
For Parkinson’s claimants specifically, the economic damages demand rigorous life-care planning. A life-care planner projects 20 to 30 years of progressive decline: medication costs that escalate as the disease advances, physical and occupational therapy, home modifications (grab bars, chair lifts, accessible bathrooms), assistive devices (canes, walkers, wheelchairs), potential deep brain stimulation surgery and its follow-up programming, and eventually skilled nursing facility placement. A forensic economist reduces that cost stream to present value. The economic floor alone — before any non-economic or punitive damages — can be substantial.
Non-economic damages encompass pain and suffering, loss of enjoyment of life, loss of bodily integrity, and psychological injury. Punitive damages are available through fraudulent concealment theories if discovery reveals that the manufacturers knew of the Parkinson’s link and intentionally concealed it from regulators and the public. Corporate documents showing knowledge of the Parkinson’s risk while representing otherwise to the EPA would be the punitive engine — and punitive damages, where available, can substantially exceed compensatory damages.
Past results depend on the facts of each case and do not guarantee future outcomes.
What to Do Right Now: The First 72 Hours
If you have been diagnosed with Parkinson’s disease and you were exposed to paraquat — or if you worked in agriculture where paraquat was used and you have neurological symptoms that have not been formally evaluated — here is what you should do, in order.
1. Get a neurological evaluation. If you have tremor, stiffness, slowness of movement, balance problems, or loss of smell, and you have not been formally diagnosed, see a neurologist who specializes in movement disorders. Parkinson’s is a clinical diagnosis — there is no blood test or definitive scan. The diagnosis is made by a specialist examining your symptoms and ruling out other causes. The earlier the diagnosis is documented, the stronger the connection between your exposure and your disease can be established.
2. Document your exposure history. Write down everything you can remember about where you worked, what chemicals you used or were exposed to, when, for how long, and under what conditions. Were you a licensed applicator? Did you mix chemicals? Did you spray from a tractor, a backpack, or an airplane? Did you work in fields that had been sprayed? What years? What crops? What regions? Every detail matters. Employment records, tax records, and applicator licensing records can corroborate your memory.
3. Do not sign anything. If you receive a notice about a class settlement, a release form, a settlement offer, or any document from an insurance company, a claims administrator, or anyone representing the chemical companies — do not sign it. Do not return it. Do not fill it out. Bring it to a lawyer first. A document you sign today can extinguish your rights permanently.
4. Do not give a recorded statement. If an insurance adjuster, a claims representative, or anyone acting on behalf of the manufacturers asks you to give a recorded statement about your exposure, your diagnosis, or your work history — decline. Anything you say will be transcribed and used to minimize or deny your claim. You are not obligated to speak to the other side’s representatives. You are obligated to protect your own case.
5. Gather your records. Employment records, pay stubs, tax returns, applicator licenses, medical records, pharmacy records, imaging reports, neurological exam notes — anything that documents where you worked, what you were exposed to, and what your medical condition is. These records are the foundation of your case. Some of them can be difficult to obtain later. Get them now.
6. Call a lawyer who handles toxic tort cases. The statute of limitations — the legal deadline to file your case — varies by state and can be complex in latent-disease cases. For toxic tort and product liability claims, most states have a 2- to 4-year deadline for personal injury, but the critical question is when the clock starts. For latent diseases like Parkinson’s that may not appear until years or decades after exposure, many states apply a discovery rule — the clock starts not when you were exposed, but when you knew or should have known that your disease was connected to the exposure. A diagnosis you only recently received may be the day your rights began, not the day they ended. But some states have statutes of repose that can cut off a claim even before discovery. You need a lawyer in your state to confirm the applicable deadline. The consultation is free. The call costs nothing. And the day you call is the day the preservation letter goes out.
Frequently Asked Questions
Does the Supreme Court ruling kill my paraquat Parkinson’s case?
No. The ruling in Monsanto Co. v. Durnell forecloses the failure-to-warn theory — the claim that the company should have put a Parkinson’s warning on the paraquat label. But three other legal theories survive: design defect (the product is inherently unreasonably dangerous in its chemical design), manufacturing defect (a specific batch deviated from the intended formulation), and fraudulent concealment (the company knew of the Parkinson’s risk and hid it from the EPA and the public). Additionally, paraquat plaintiffs have a unique preemption defense that Roundup plaintiffs lacked: the EPA never made a definitive finding on the paraquat-Parkinson’s link, so the Durnell preemption logic — which depended on the EPA having affirmatively cleared glyphosate’s cancer risk — may not apply with the same force to paraquat claims.
I used Roundup and got non-Hodgkin lymphoma — is my case over?
Not necessarily, but it is harder. The Durnell ruling foreclosed the failure-to-warn theory that anchored the largest Roundup verdicts. Design defect and fraudulent concealment theories remain available. Bayer has proposed a $7.25 billion class settlement for remaining and future Roundup claims, with a hearing scheduled for July. You should have an individual evaluation of your case against the class settlement terms to determine whether your case is worth more on its own. No one should accept a class settlement without understanding whether their individual case has greater value.
How long do I have to file a paraquat Parkinson’s lawsuit?
Statutes of limitations vary by state — most states have a 2- to 4-year deadline for personal injury and product liability claims. The critical question for toxic tort cases is when the clock starts. For latent diseases like Parkinson’s that may not appear until years or decades after exposure, many states apply a discovery rule: the deadline runs from when you knew or should have known that your disease was connected to the exposure, not from the date of exposure itself. A recent diagnosis may be the start of your clock, not the end. However, some states have statutes of repose that impose an outer deadline regardless of discovery. You need a lawyer in your state to confirm the applicable deadline. Do not assume you have plenty of time, and do not assume you are too late — call and find out.
What if I was exposed to paraquat but haven’t been diagnosed with Parkinson’s yet?
Get a neurological evaluation. Parkinson’s is a clinical diagnosis made by a movement-disorder specialist. If you have symptoms — tremor, stiffness, slowness of movement, balance problems, loss of smell — get them documented by a neurologist. If you have no symptoms but were heavily exposed, discuss monitoring with your doctor. Do not wait for symptoms to become severe before seeking evaluation — early documentation strengthens the connection between exposure and disease.
I’m a farmworker and I don’t know if I was exposed to paraquat — what should I do?
You are not alone. Farmworkers rarely know exactly what pesticides they are encountering — the chemicals arrive in tanks and spray rigs, often labeled in English, often applied by someone else while the worker is in the field. Paraquat is a restricted-use pesticide, meaning it can only be applied by a licensed applicator. But workers in fields that have been sprayed, workers who mix or load chemicals, and workers who handle sprayed crops can all be exposed. Write down everything you remember about where you worked, what crops, what years, what chemicals you can recall, and whether spraying occurred near you. Employment records and agricultural-use records can help identify what was applied. A lawyer who handles toxic tort cases can help investigate your exposure history.
Will the proposed $7.25 billion Roundup settlement cover my case?
That depends on whether your case is a Roundup (glyphosate) case or a paraquat case. The $7.25 billion class settlement proposed by Monsanto/Bayer is for Roundup claims — it does not cover paraquat claims. Paraquat claims are a separate litigation against Syngenta and Chevron, consolidated in a federal court in the Southern District of Illinois. If you have a paraquat Parkinson’s claim, the Roundup settlement does not apply to you. If you have a Roundup non-Hodgkin lymphoma claim, you should have your case evaluated individually against the class settlement terms.
What is the difference between failure-to-warn and design defect?
Failure-to-warn says the company should have put a warning on the label — and that theory is now largely preempted by the Supreme Court’s Durnell ruling. Design defect says the product itself is unreasonably dangerous in its chemical design, regardless of what the label says — and that theory is not preempted because it does not require any change to the EPA-approved label. The question in a design defect case is not “what should the label have told you?” but “should this product have been designed this way at all?” That is a fundamentally different legal question, and it survives Durnell.
Can I still get punitive damages in a paraquat case?
Yes — potentially. Punitive damages are available through the fraudulent concealment theory. If discovery reveals that the manufacturer knew of the Parkinson’s risk — through its own internal studies, its scientists’ research, or its analysis of the scientific literature — and intentionally concealed, minimized, or misrepresented that risk to the EPA, the scientific community, and the public, punitive damages may be available. Punitive damages are designed to punish and deter conduct that is worse than ordinary negligence — conduct that involves knowledge of a risk and a deliberate decision to hide it. The discovery target is the gap between what the company’s internal documents show it knew and what it told the world.
I’m undocumented — can I still file a lawsuit?
Your immigration status does not determine your right to sue for injuries caused by a defective product or a company’s misconduct. The civil justice system does not require citizenship or legal residency to pursue a claim. If you were exposed to paraquat and developed Parkinson’s disease, you have the same right to seek compensation as any other person. A lawyer who handles toxic tort cases can explain your rights and protections. We serve our clients fully in Spanish — consultations are available without an interpreter.
How much is my paraquat Parkinson’s case worth?
Case value depends on the specific facts of your case: the strength of your exposure proof, the quality of your medical documentation, the jurisdiction where your case would be filed, whether your case is part of the MDL or on an individual track, and what the discovery process reveals about the manufacturer’s internal knowledge. Individual claimant values in comparable toxic tort cases range from approximately $250,000 on the low end to $5,000,000 or more on the high end. For Parkinson’s claimants, the economic damages alone — projected across 20 to 30 years of progressive decline — can be substantial before any non-economic or punitive damages are added. No lawyer can guarantee a specific outcome, and past results depend on the facts of each case and do not guarantee future outcomes. But a free consultation can give you an honest assessment of what your case may be worth based on your specific circumstances.
Why This Firm
We are Attorney911 — The Manginello Law Firm, PLLC. We are Legal Emergency Lawyers. We have been in practice since 2001 — more than 24 years — and we have recovered more than $50 million for our clients. We handle toxic tort cases because we believe that the companies that poison workers and then hide the evidence should be the ones who pay — not the families who were never told the danger was there.
Ralph P. Manginello is our Managing Partner. He has been licensed in Texas since November 6, 1998 — more than 27 years. He is admitted to practice in the U.S. District Court for the Southern District of Texas, including federal court. He was a journalist before he was a lawyer, which means he knows how to find a story the other side hoped would stay buried. He speaks Spanish. He has spent his career in courtrooms, including federal court, fighting for people who were hurt by companies that cut corners and then tried to erase the evidence.
Lupe Peña is our Associate Attorney. He is a former insurance-defense attorney — he spent years inside a national defense firm, in the rooms where adjusters and their software decided how to deny, delay, and devalue claims exactly like yours. He knows how the other side values a case, how they pick their experts, how they set their reserves, and how they plan their delays. Now he uses that knowledge for injured clients. He is fluent in Spanish — he conducts full consultations in Spanish without an interpreter. He is a third-generation Texan with family roots that run to the King Ranch. When a farmworker in the Rio Grande Valley calls with a tremor they cannot explain and a work history they can barely piece together, Lupe is the person who can sit across the table and speak to them in the language they pray in.
We have fought for workers exposed to toxic chemicals — refinery workers exposed to benzene and asbestos, men who were never told that the air they breathed at work was going to give them cancer decades later. That fight is different from the paraquat fight in its specifics, but it is the same in its bones: a company that knew, or should have known, that its product was dangerous, and a worker who was never told. The medicine, the corporate-accountability fight, the evidence-preservation work, the life-care planning — these do not change because the chemical is paraquat instead of benzene. The fight is the same.
We work on contingency. That means we do not get paid unless we win your case. The consultation is free. The call costs nothing. You will speak to a live person, 24 hours a day, 7 days a week — not an answering service. The fee is 33.33% before trial and 40% if the case goes to trial. Those numbers are stated plainly because you should know exactly what you are agreeing to before you agree to it.
If you call, here is what happens: we listen. We ask questions about where you worked, what you were exposed to, what your medical condition is, and when you were diagnosed. We tell you honestly whether we think you have a case. If we do, we explain the path forward — the preservation letter, the exposure investigation, the medical proof, the expert witnesses, the discovery process. If we do not, we tell you that too. If we are not the right fit for your case, we will tell you. We are not going to take a case we cannot win.
Hablamos Español. If you or a family member was exposed to paraquat and has been diagnosed with Parkinson’s disease — or if you worked in agriculture and have symptoms you cannot explain — call us. We will speak to you in Spanish. We will listen. And we will tell you the truth about what we can do.
The Supreme Court narrowed the door. It did not close it. The companies that made paraquat, sold it, and profited from it for half a century while more than 70 countries banned it are still answerable — on theories the Supreme Court left untouched, for harm the EPA never decided was safe, with evidence that is still out there if someone moves fast enough to freeze it.
Call 1-888-ATTY-911. The consultation is free. The call is confidential. And the day you call is the day the clock starts working for you instead of against you.
Past results depend on the facts of each case and do not guarantee future outcomes. This page is legal information, not legal advice. Every case turns on its own facts. Contacting the firm is free and confidential.